Pharmacogenomics of vitamin K antagonists

Simple item page
dc.contributor.authorGuzman Oyarzo, Neftali
dc.contributor.authorVega, Mario
dc.contributor.authorReyes, Franco
dc.contributor.authorGuzman-Oyarzo, Dina
dc.contributor.authorAndaur Rademacher, Marcela
dc.contributor.authorBoguen, Rodrigo
dc.contributor.authorLetelier, Pablo
dc.date2020
dc.date.accessioned2021-04-30T17:07:24Z
dc.date.available2021-04-30T17:07:24Z
dc.description.abstractThere is an important interindividual variability in dose requirement for coumarinic anticoagulants, which could be explained by genetic and non-genetic factors. Among hereditary factors, there are gene polymorphisms that code the therapeutic target and the main enzyme responsible for their metabolism. However, there are other candidate genes that could modulate dose requirements. The is a paucity of pharmacogenomic platforms to determine dose requirements of coumarinics in the Chilean population. Therefore, algorithms considering different variables to adjust individual dosages are required. Herein, we analyze the available evidence about factors that can modify the effects of vitamin K antagonists and that should be incorporated to dosing algorithms.
dc.identifier.citationREVISTA MEDICA DE CHILE,Vol.148,1307-1314,2020
dc.identifier.urihttp://repositoriodigital.uct.cl/handle/10925/4177
dc.language.isoes
dc.publisherSOC MEDICA SANTIAGO
dc.sourceREVISTA MEDICA DE CHILE
dc.subject.englishAnticoagulants
dc.subject.englishCoumarins
dc.subject.englishPharmacogenomic Variants
dc.titlePharmacogenomics of vitamin K antagonists
dc.typeReview
uct.catalogadorWOS
uct.indizacionSCI
Files
Collections
MigraciĆ³n Web of Science